Abstract
Dengue virus serotype 2, genotype Cosmopolitan (DENV-2-GII), is one of the most widespread DENV strains globally. In the Americas, DENV-2 epidemics has been dominated by DENV-2 genotype Asian-American (DENV-2-GIII) and the first cases of DENV-2-GII were only described in 2019, in Peru, and in 2021 in Brazil. To gain new information about the circulation of DENV-2-GII in Brazil, we sequenced 237 DENV-2 confirmed cases sampled between March 2021 and March 2023 and revealed that DENV-2-GII is already present in all geographic regions of Brazil. Phylogeographic analysis inferred that DENV-2-GII was introduced at least four times in Brazil, between May 2020 and August 2022, generating multiple clades that spread throughout the country with different success. Despite multiple introductions of DENV-2-GII, analysis of the country-wide laboratory surveillance data showed that the Brazilian dengue epidemic in 2022 was dominated by DENV-1 in most states. We suggest that massive circulation of DENV-2-GIII in previous years in Brazil might have created a population immune barrier for widespread transmission of DENV-2-GII, leading to sustained cryptic circulation and localized outbreaks of this new genotype. In summary, our study stresses the importance of arboviral genomic surveillance to close monitoring and better understand the potential impact of DENV-2-GII in the coming years.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge all data contributors, i.e., authors and their originating laboratories responsible for obtaining and timely submitting dengue virus genomes, including metadata, via GenBank or other public databases. We appreciate the support of FIOCRUZ Genomics Surveillance Network members. Funding support: FAPEAM (Universal/AM call 2019; Rede Genomica de Vigilancia em Saude - REGESAM); Inova Fiocruz/Fundacao Oswaldo Cruz (Inova Amazonia); Departamento de Ciencia e Tecnologia (DECIT) of the Brazilian MoH; G.B. is supported by CNPq through a productivity research fellowships (304883/2020-4).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Instituto Oswaldo Cruz (CAAE: 90249218.6.1001.5248).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Lists of authors and their affiliations appear at the Supplementary Consortia List
Data Availability
All data produced in the present study are available upon reasonable request to the authors
